Rallybio Announces Transformative Reverse Merger with Candid Therapeutics, Existing Shareholders Face Significant Dilution
RLYB has more than doubled off its 52-week low of $1.761.
Summary
Rallybio Corp announced a reverse merger with Candid Therapeutics, where existing Rallybio shareholders will own only 3.65% of the combined company, alongside a $505.5 million concurrent financing for Candid and uncertain CVRs for Rallybio's legacy assets.
Key Events · M&A and Partnerships · RLYB
-
Proposed Reverse Merger with Candid Therapeutics
Rallybio entered into a merger agreement with Candid Therapeutics on March 1, 2026. Post-merger, existing Rallybio equityholders are expected to own approximately 3.65% of the combined company, while Candid equityholders (including concurrent financing investors) will own 96.35%.
-
Significant Concurrent Financing for Candid
Candid Therapeutics secured an aggregate commitment of approximately $505.5 million in concurrent financing, which will convert into shares of the combined Rallybio entity.
-
Contingent Value Rights (CVRs) for Legacy Assets
Rallybio shareholders will receive CVRs, entitling them to a pro rata share of net proceeds from the disposition of Rallybio's pre-Merger assets and cash from a July 2025 agreement with Recursion Pharmaceuticals. The company will use commercially reasonable efforts for one year post-closing to monetize these assets.
-
RLYB212 Program Discontinued
In April 2025, Rallybio discontinued its RLYB212 program for the prevention of FNAIT due to Phase 2 clinical trial data showing an inability to achieve target concentrations for efficacy.
Analysis · RLYB · Life Sciences
This 10-K filing details a pivotal and highly dilutive strategic shift for Rallybio Corp. The proposed reverse merger with Candid Therapeutics will result in current Rallybio shareholders owning a mere 3.65% of the combined entity, effectively transforming Rallybio into Candid. While Candid secured a substantial $505.5 million in concurrent financing, this capital primarily benefits the new combined company's pipeline, not Rallybio's legacy assets. Existing Rallybio shareholders will receive Contingent Value Rights (CVRs) for their pre-Merger assets, but the value and timing of these payouts are uncertain. This transaction, coupled with the discontinuation of the RLYB212 program and prior workforce reductions, signals a significant restructuring and a challenging outlook for existing Rallybio investors due to the substantial dilution and change in strategic direction. The recent 1-for-8 reverse stock split, while resolving Nasdaq compliance issues, underscores the company's prior stock price weakness.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $9.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.8M. The 52-week trading range was $1.76 to $11.49. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.